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Variations in the HCR (Pg8) Gene are Unlikely to be Causal
for Familial Psoriasis
To the Editor:
In a recent report Asumalahti et al identi®ed 12 coding variants
within gene HCR (Pg8) of the HLA class I region on chromosome
6 (Asumalahti et al, 2000). Two of these variants, C®T transitions
at nucleotide positions of 251 and 269, form an allele (the ``TT
allele'') that is strongly associated with psoriasis. Based on this
®nding, it was suggested that HCR may have a role in the
pathogenesis of psoriasis. We recently reported the ®ne mapping of
the PSORS1 susceptibility locus to a 60 kb segment of the HLA
class I region, between the HLA-C and corneodesmosin (CDSN)
genes (Nair et al, 2000). Using 34 closely spaced microsatellite
markers, we identi®ed 66 relatively homogeneous clusters of
haplotypes in 478 families and examined their association with
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psoriasis by the transmission/disequilibrium test. We found that
cluster numbers 17±25 conferred risk for psoriasis and possessed
identical alleles at eight contiguous markers spanning the 60 kb
interval, which we termed risk haplotype 1 (RH1). RH1 is in
strong disequilibrium with HLA-Cw6 in clusters 18±25 and with
HLA-Cw8 in cluster 17. All risk haplotype clusters in our sample
carried RH1, but none of the nonrisk clusters did. Due to the close
proximity of RH1 to the HCR gene (the telomeric end of RH1
lies only 25 kb from the centromeric end of HCR), we wished to
determine whether the psoriasis risk haplotypes we identi®ed carry
the HCR candidate allele identi®ed by Asumalahti et al and
whether the nonrisk haplotypes do not. We PCR ampli®ed exon 2
of the HCR gene from genomic DNA of 32 individuals
representative of the seven most common risk and ®ve most
common nonrisk haplotypes in our sample using the primers CAC
CTG CAC TAA CCT GTC TTTG and TTT CTA CCC CTG
CAT TCA CC from Asumalahti et al. The gel-puri®ed PCR
products were directly sequenced for the region containing HCR
nucleotides 251 and 269. The results (Table I) show that
chromosomes bearing risk haplotypes 17 and 18 carry C at
nucleotides 251 and 269, whereas risk clusters 19, 21, 22, 23, and
25 carry T at these positions. Among nonrisk clusters, cluster 26
carried T at both positions in all subjects; the remaining nonrisk
clusters carried C at both positions. Because haplotype clusters 17
and 18 confer risk but do not carry the C®T variants at nucleotides
251 or 269 of HCR, and because haplotype cluster 26 does not
confer risk but does carry these C®T variants, we conclude that
these variations in HCR are not causal for psoriasis. Rather, the
observed disease association re¯ects the existence of strong linkage
disequilibrium between HCR and PSORS1. Asumalahti et al
observed that the Cw*0602 allele at HLA-C conferred a higher
relative risk for psoriasis than did the TT allele of HCR. This
observation is readily explained by our observations: cluster 26,
which carries HLA-Cw7, HLA-B8, and the TT allele of HCR,
does not confer risk but is one of the most common HLA B/C
haplotypes in Caucasians (Tsuji et al, 1992). The high prevalence of
cluster 26 therefore ``dilutes'' the relative risk associated with
carriage of the TT allele at HCR. In contrast, possession of RH1
confers higher risk for psoriasis than does possession of HLA-Cw6
(Nair et al, 2000).
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Table I. HLA and HCR alleles associated with microsatellite haplotype clusters
Haplotype cluster
Association
with
psoriasis
Number
haplotypes
tested
HLA Class I haplotype
HLA-B HLA-C RH1 HCR
nt 251
HCR
nt 269
Risk clusters
17 + 5 65 8 + C C
18 + 4 45 6 + C C
19 + 5 various 6 + T T
21 + 5 13 6 + T T
22 + 5 13 6 + T T
23 + 5 37 6 + T T
25 + 5 57 6 + T T
Non-risk clusters
14 ± 5 7 7 ± C C
26 ± 5 8 7 ± T T
48 ± 4 62 3 ± C C
56 ± 5 44 16 ± C C
63 ± 4 44 5 ± C C
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